Jorge Alejandro Salto-Sevilla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jorge Alejandro Salto-Sevilla has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Fernando Caloca-Camarena
Programa de Doctorado en Farmacología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico; Instituto de Biología Molecular en Medicina y Terapia Génica, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico
2 shared publications - Hugo Christian Monroy-Ramirez
Universidad de Guadalajara
2 shared publications - Juan Armendariz-Borunda
Universidad de Guadalajara
2 shared publications - Marina Galicia-Moreno
Instituto de Biología Molecular en Medicina y Terapia Génica, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, México
2 shared publications - Roberto Flores-Peña
Programa de Doctorado en Farmacología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico; Instituto de Biología Molecular en Medicina y Terapia Génica, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico
2 shared publications - Scarlet Arceo-Orozco
Instituto de Biología Molecular en Medicina y Terapia Génica, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, México
2 shared publications
Latest Publications
- 23 May 2026
- Published by Elsevier in Cellular Signalling
- Vol. 145, 112614
N-acetylcysteine–induced transcriptomic reprogramming regulates Nrf2-mediated signaling and redox homeostasis in experimental hepatocellular carcinoma
- 23 May 2026
- Published by Elsevier in Cellular Signalling
- Vol. 145, 112614
N-acetylcysteine–induced transcriptomic reprogramming regulates Nrf2-mediated signaling and redox homeostasis in experimental hepatocellular carcinoma
- Open Access
- 10 August 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (8) , 979
Naringin and Naringenin in Liver Health: A Review of Molecular and Epigenetic Mechanisms and Emerging Therapeutic Strategies
Liver diseases have become a significant global health concern, driving increased interest in naturally occurring compounds as adjunctive treatments for managing these conditions. Flavonoids, a class of natural polyphenols found in plants and fruits, offer a broad spectrum of potential health benefits due to their applications in nutraceuticals, pharmaceuticals, and cosmetics. Among them, naringin (NARI) and naringenin (NAR), which are abundant in citrus fruits, have attracted considerable attention. Numerous studies have investigated the therapeutic effects of NARI and NAR across different stages of liver disease. This review highlights recent research on the impact of these flavonoids in alcohol-related liver disease and metabolic dysfunction-associated fatty liver disease (MASLD). It also explores the molecular mechanisms and epigenetic modifications through which NARI and NAR contribute to preventing liver disease progression. Finally, this work discusses recent progresses and future perspectives, emphasizing the role of innovative nanocarriers, nanoparticles, and drug delivery strategies in enhancing the efficacy and bioavailability of these promising compounds to improve liver health.
- 10 August 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (8) , 979
Open AccessNaringin and Naringenin in Liver Health: A Review of Molecular and Epigenetic Mechanisms and Emerging Therapeutic Strategies
Liver diseases have become a significant global health concern, driving increased interest in naturally occurring compounds as adjunctive treatments for managing these conditions. Flavonoids, a class of natural polyphenols found in plants and fruits, offer a broad spectrum of potential health benefits due to their applications in nutraceuticals, pharmaceuticals, and cosmetics. Among them, naringin (NARI) and naringenin (NAR), which are abundant in citrus fruits, have attracted considerable attention. Numerous studies have investigated the therapeutic effects of NARI and NAR across different stages of liver disease. This review highlights recent research on the impact of these flavonoids in alcohol-related liver disease and metabolic dysfunction-associated fatty liver disease (MASLD). It also explores the molecular mechanisms and epigenetic modifications through which NARI and NAR contribute to preventing liver disease progression. Finally, this work discusses recent progresses and future perspectives, emphasizing the role of innovative nanocarriers, nanoparticles, and drug delivery strategies in enhancing the efficacy and bioavailability of these promising compounds to improve liver health.